Novel Inflammasome‐Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early‐Stage Non‐Small Cell Lung Cancer

Novel Inflammasome‐Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early‐Stage Non‐Small Cell Lung Cancer

Immune checkpoint inhibitors (ICI) for early‐stage non‐small cell lung cancer (NSCLC) have been approved to improve outcomes and reduce recurrence. Biomarkers for patient selection are needed. In this paper, we proposed an inflammasome‐based risk score (IRS) system for prognosis and prediction of IC...

Full description

Bibliographic Details
Main Authors: Chen, H.-Y (Author), Dai, Y.-H (Author), Shen, P.-C (Author), Tsao, C.-C (Author), Wang, Y.-F (Author), Wu, H.-H (Author), Wu, W.-T (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
CASP‐1
early‐stage NSCLC
GSDMD
IL18
IL1B
immune checkpoint inhibitor
immunotherapy
inflammasome
SLAMF8
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items